Novoheart is proud to announce that we have been successfully selected as one of "The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area 2018" , as one of 5 enterprises from Hong Kong on the list.
The award ceremony was held in Guangzhou on September 7, 2018, where VP Scientific Development Dr. Gabriel Wong received the award on behalf of Novoheart. "The Top 50 of Innovative Biotechnology Enterprises in Guangdong-Hong Kong-Macau Greater Bay Area 2018" selection is co-organized by ZDVC Research (中创产业研究院), KPMG China and the Guangdong Medical Valley. The selection process lasted for three months, led by a panel of advisors from government agencies, third-party research organizations, professional investment entities and medical institutions.
More information from the official website: